tabersonine has been researched along with angiotensin ii in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chattipakorn, N; Chen, R; Chen, Y; Dai, C; Huang, W; Liang, G; Luo, W; Shen, S; Wang, J; Wang, Z | 1 |
1 other study(ies) available for tabersonine and angiotensin ii
| Article | Year |
|---|---|
Tabersonine attenuates Angiotensin II-induced cardiac remodeling and dysfunction through targeting TAK1 and inhibiting TAK1-mediated cardiac inflammation.
Topics: Angiotensin II; Animals; Cardiomegaly; Fibrosis; Heart Failure; Indole Alkaloids; Inflammation; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Quinolines; Rats; Signal Transduction; Ventricular Remodeling | 2022 |